Figure 4
Eltrombopag does not enhance proliferation or alter apoptosis of primary human CD138+ myeloma cells. Human primary CD138+ multiple myeloma cells from patients with relapsed multiple myeloma (n = 7) were incubated with varying concentrations of eltrombopag in the presence or absence of G-CSF (10 ng/ml) and EPO (3 U/ml) and in the presence or absence of lenalidomide (1 μM) and bortezomib (10 nM). (A) Cell viability was determined by measuring fluorescence signals at 535Ex/595Em using the CellTiter Blue Assay (*p < 0.01). (B) Apoptosis was assessed by measuring activation of caspase-3 and −7 (*p < 0.05). Data are presented as mean ± S.E. of combined experiments on seven individual patient samples, each performed in triplicate. ELT = Eltrombopag; TPO = thrombopoietin; CTRL = control; Len = lenalidomide; Btz = bortezomib.